Clinical aspects of visceral leishmaniasis caused by L. infantum in adults. Ten years of experience of the largest outbreak in Europe: what have we learned?

Table 6 Dose and clinical outcome in patients with VL according to their immunological status

^aUsual LAB standard dose (see text): IC-VL 18–21 mg/kg; HIV-VL 30–40 mg/kg; IS-VL 21–40 mg/kg
^b3 IC-VL patients with solid neoplasms were treated with 21, 30 and 40 mg/dl each, with no relapses
^cRelapsed and died during retreatment
^dThis patient was clinically cured after treatment but voluntarily stopped secondary prophylaxis and relapsed
^eOne patient was clinically cured after treatment but voluntarily stopped secondary prophylaxis and relapsed
^fLack of initial response, cured after retreatment
Abbreviations: LAB, liposomal B amphotericin; ABLC, amphotericin B lipid complex; IC-VL, visceral leishmaniasis in immunocompetent patients; HIV-VL, visceral leishmaniasis in patients with HIV; IS-VL, visceral leishmaniasis in immunosuppressed patients (receiving steroids, methotrexate, anti-TNF)

ISSN: 1756-3305